The new WHO guideline is a long-term injection that can be acted for long-term Lena Kapar, which can be acted for a long time for HIV prevention, and a long-term injectable cabotegravir for treatment of pharmaceuticals, and an oral pill MK-8527 African African III exams in one month of MERCK Enlarge progress.
IAS 2025, 13th IAS Conference on HIV ScienceToday, as the issue of global funding increases, we opened the door today in a request to accelerate access to long -term HIV prevention and treatment innovation. 4,000 participants are attending KIGALI, RWANDA and virtually IAS 2025. The IAS conference on HIV science is the world’s most influential meeting for HIV research and applications.
Dr. Sabin NSANZIMANA, the Minister of Health, said in a press conference with the title of “breakthrough innovation in the crisis: the future of HIV innovation.”
“Rwanda’s experience in HIV reactions over the last decades shows what is possible when investing in strategic partnerships with a recent response to the infectious diseases.” Dr. Sabin Nsanzimana, the Ministry of Health, said. “We achieve the UNAIDS 95-95-95 goals before the schedule and continue to take advantage of the state-of-the-art science, including long-term drugs, to provide more goals and integrated arbitration. Our shared responsibility is to ensure that this innovation will not only develop and agree with everyone.”
“Today, it shows an important moment in the journey that expands the choice, expands the choice of people who are vulnerable to HIV and improves the results.” Dr. Beatriz Grinsztejn, chairman of the IAS, said. “The new WHO guidelines, breakthrough license contracts and promising studies can be seen that long -term HIV prevention and treatment are getting closer to become part of everyday treatment, which is possible when researchers, industry, global health institutions and communities work together. You need to use the necessary funds and resources.
One of the main announcements of the opening meeting was the New World Health Organization (WHO) guideline, which recommends long -term injection Lenacapavir for HIV prevention, and emphasized the will for a fair approach to this innovation. “We have tools and knowledge to end AIDS due to public health problems.” Dr. MEG Doherty, who is a WHO director of the WHO Global HIV Department, Hepatitis and STI Program, said by the recipient director for science, research, evidence and health. “What we need now is the bold implementation of these recommendations, based on equality and the community runs.”
Dr. Tedros Adhanom Ghebreyesus’s statement has been issued to support new guidelines.
Tedros Adhanom Ghebreyyeesus said, “HIV vaccines are ambiguous, but Lenacapavir is the next best. “With the recent approval of the FDA, the launch of WHO’s new guidelines is going on to expand access to this powerful tool.
The new license agreement between the pharmaceutical patent pool and VIIV health care has been announced to expand the access to the long -lasting Cabotegravir for HIV treatment. “To include long -term activities for HIV treatment, expanding the license with VIIV Healthcare is a significant progress for fair access.” Esteban Burrore, the director of the strategy, policy and market approach of pharmaceutical patent pool, said.
“As the first complete long -term HIV treatment therapy, it responds to the community’s long -term calls for options to maintain virus oppression without the need for daily drug treatment, which shows not only innovation and access, but also reaches the hand, now we can increase the quality of the general license. We look forward to accelerating our general license development. ”
A new study of MSDs on MK-8527, one oral pill, to prevent HIV, has also been presented. Candidates are advancing to a three -stage exam in Africa. Research co -author Dr. Global clinical development of Rebeca Plank, Distinguished Scientist, and MSD Research Laboratories shared new data.
“MK-8527’s II Study on IAS 2025 shows advantageous safety and adhesive profiles with pharmacokinetic data that support an oral medication per month in a three-phase study. It was designed to evaluate the profile. We are proud to partner with the Gates Foundation and International Clinical Research Center and conduct HIV prevention research.
Advocates have urged global leaders to guarantee a fair access to the new HIV prevention and treatment options. “Long lasting HIV prevention and treatment can only change life if people can actually get them.” HIV and AIDS anti -advocates, Ivette Raphael. “We can’t repeat the past mistakes that have been new to those who have new medicines but the most needed people. We need a clear plan and real funds to be reliable in the local community. Science has provided powerful tools.
Mary Mahy emphasized the continuous gap between the UNAIDS Director Data Impact, which is the most affected by HIV, prevention and treatment of major population and regions that are most affected by the HIV.
MAHY said, “By the end of 2024, 73%of all HIVs have achieved viral sex oppression, and this impressive progress makes people suffering from HIVs healthy and reduces HIV, but the crisis of financing ends this difficult progress in response to HIV.
Unaids Managing Director Winnie byanyima We have issued a global update that emphasizes the continuous gap between HIV prevention and treatment access, especially the main population and the continuous gap of the most difficult areas. “We are seeing a massive interruption of international HIV financing, which caused a systematic impact on the world’s HIV response, causing great confusion about HIV treatment and preventive programs around the world.” It is in DNA to face crisis and escape the crisis. The state is elastic, we do not give up, and we are trying to continue to end AIDS with the government and the community. “
The IAS 2025 will continue until July 17, featuring hundreds of sessions and presentations that focus on translating scientific breakthroughs as a real influence, focusing on solutions to areas and populations that are most affected by HIV.
In addition to today’s announcement International AIDS Society Journal (JIA) Some important topics have been announced before IAS 2025. These are as follows: “African PEP: Overview, Opportunity and Challenge”, Euphemia Sibanda, Julie Fox and Peter Godfrey-Faussett; “Select -based HIV prevention market expansion”, Guest was edited by Virginia A. Fonner, Nicolette P. NAIDOO and James Ayieko. Guests edited by Anna Grimsrud, Charles B. Holmes, and Linda Sande are “offering differentiated services -beyond integration and other health demands”. Each collection examines the main tasks and opportunities for the future of HIV response.
Click here to see more news in IAS 2025.
Pose is an Official Media Partner of IAS 2025.
